Page 16 - விசை கவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Детские кружки в Атырау станут бесплатными
express-k.kz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from express-k.kz Daily Mail and Mail on Sunday newspapers.
Fälle von Infizierten in Leichlingen und im Rheinisch-Bergischen Kreis
ksta.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksta.de Daily Mail and Mail on Sunday newspapers.
India, Bangladesh Boost Counter-Terror Cooperation As 10-Day Military Drills Conclude
April 15, 2021
India and Bangladesh strengthened their counterterrorism cooperation through a 10-day multinational military exercise, ‘Shantir Ogroshena’ (Front Runner of the Peace).
The military drills, which concluded on Monday, marked the golden jubilee of the Bangladesh liberation war fought with India’s military assistance.
Held at Bangabandhu Senanibas (BBS) in Bangladesh, the exercise saw the participation of India, Bangladesh, Bhutan, and Sri Lanka. The US, the UK, Russia, Turkey, Saudi Arabia, Kuwait, and Singapore were observers of the proceedings.
The Indian Army said the military exercises were aimed at strengthening defense ties and enhancing interoperability among the neighboring countries to ensure effective peacekeeping operations.
Румынский уезд Муреш готов развивать сотрудничество с белорусскими регионами в деловой, медицинской, образовательной и культурной сферах
sb.by - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sb.by Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
Since the approval of Vitravene (for the treatment of cytomegalovirus retinitis) in 1998, antisense oligonucleotide (ASO) therapies have evolved into a prominent class of therapeutics. In addition to the seven drugs, based on such molecules, that are commercially available, around 160 candidates are under development. Examples of recently approved antisense therapeutics include (in reverse chronological order) Viltepso (duchenne muscular dystrophy, March 2020), Vyondys 53 (duchenne muscular dystrophy, December 2019) and Waylivra (hereditary transthyretin-mediated (hATTR) amyloidosis, May 2019).
Given their ability to target the root cause of diseases, at the protein expression level, these disease-modifying interventions have potential applications across a wide range of therapeutic areas (including but not limited to oncological disorders, neurodegenerative disorders, respiratory disorders, and even certain